Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.66 |
| ▸ | FNTA | P49354 | 2/20 | 0.61 |
| ▸ | FNTB | P49356 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.50 |
| ▸ | ITGAV | P06756 | 3/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5340895 | 0.92 | L3MBTL1 (0.59) | L3MBTL1FFAR1FNTAFNTBKMT2A | |
| SCHEMBL4453571 | 0.91 | FFAR1 (0.78) | L3MBTL1FFAR1FNTAFNTBKMT2A | |
| SCHEMBL10200947 | 0.90 | GABBR2 (0.64) | L3MBTL1FFAR1FNTAFNTBKMT2A | |
| SCHEMBL6484578 | 0.86 | FFAR1 (0.66) | L3MBTL1FFAR1KMT2AATMLDHA | |
| SCHEMBL28854188 | 0.85 | FFAR1 (0.59) | L3MBTL1FFAR1FNTAFNTBKMT2A | |
| SCHEMBL27829876 | 0.85 | ALDH1A1 (0.62) | L3MBTL1FFAR1FNTAFNTBLDHA | |
| SCHEMBL15782118 | 0.84 | AKR1C3 (0.62) | L3MBTL1FFAR1 | |
| SCHEMBL16624890 | 0.84 | L3MBTL1 (0.81) | L3MBTL1FFAR1FNTAFNTBATM | |
| SCHEMBL16249736 | 0.83 | GABBR2 (0.61) | L3MBTL1FFAR1FNTAFNTBKMT2A | |
| SCHEMBL4478662 | 0.83 | FFAR1 (0.56) | L3MBTL1FFAR1KMT2AATMLDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011085445-A1 | FLOTATION REAGENTS | TEEBEE HOLDINGS PTY LTD (AU) | 2011-07-21 | — | — | WO | claimed |
| EP-4709719-A1 | 5-CYANO-1H-IMIDAZOLE-2-CARBOXAMIDE COMPOUNDS AS CSF1R INHIBITORS | Modulo Bio, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12551490-B2 | Heterocyclic modulators of lipid synthesis | SAGIMET BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| WO-2024254440-A1 | 5-CYANO-1H-IMIDAZOLE-2-CARBOXAMIDE COMPOUNDS AS CSF1R INHIBITORS | MODULO BIO, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-20240400552-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2024-12-05 | — | — | US | disclosed |
| CN-117550943-A | Based on CO 2 Method for participating in controllable synthesis of polycarboxylic acid compounds | 四川大学 | 2024-02-13 | — | — | CN | disclosed |
| US-20230405016-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2023-12-21 | — | — | US | disclosed |
| CN-117247317-A | Based on CO 2 Method for synthesizing dicarboxylic acid/tricarboxylic acid compound | 四川大学 | 2023-12-19 | — | — | CN | disclosed |
| CN-116139138-A | Heterocyclic modulators of lipid synthesis | 3-V生物科学股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-11622968-B2 | Heterocyclic modulators of lipid synthesis | SAGIMET BIOSCIENCES INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-4323511-A | Steroid derivatives and their use in radioimmunoassays | E. R. SQUIBB & SONS, INC. (US) | 1982-04-06 | — | — | US | disclosed |
| EP-0005558-B1 | STEROID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN RADIOIMMUNOASSAYS | E.R. Squibb & Sons, Inc. (US) | 1982-01-27 | — | — | EP | disclosed |
| EP-0005834-B1 | VITAMIN B-12 DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN RADIOIMMUNOASSAYS | E.R. Squibb & Sons, Inc. (US) | 1981-10-14 | — | — | EP | disclosed |
| US-4248783-A | Steroids having a 3-(4-hydroxyphenyl)pentanedioic acid monohydrazide substituent | E. R. SQUIBB & SONS, INC. (US) | 1981-02-03 | — | — | US | disclosed |
| US-4243608-A | 3-(4-Hydroxyphenyl)pentanedioic acid, monohydrazide, derivatives and analogs | E. R. SQUIBB & SONS, INC. (US) | 1981-01-06 | — | — | US | disclosed |
| US-4230621-A | TRACERS, HYDROXYPHENYLGLUTARIC ACID DERIVATIVES | E. R. SQUIBB & SONS, INC. (US) | 1980-10-28 | — | — | US | disclosed |
| US-4221725-A | CHEMICAL INTERMEDIATE | E. R. SQUIBB & SONS, INC. (US) | 1980-09-09 | — | — | US | disclosed |
| US-4209614-A | Vitamin B12 derivative suitable for radiolabeling | E. R. SQUIBB & SONS, INC. (US) | 1980-06-24 | — | — | US | disclosed |
| EP-0005834-A1 | Vitamin B-12 derivatives, process for their preparation and their use in radioimmunoassays | E.R. Squibb & Sons, Inc. (US) | 1979-12-12 | — | — | EP | disclosed |
| EP-0005558-A1 | Steroid derivatives, process for their preparation and their use in radioimmunoassays | E.R. Squibb & Sons, Inc. (US) | 1979-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230405016-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | L3MBTL1 2557/4885FFAR1 125/4885FNTA 133/4885 |
| US-20240400552-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | L3MBTL1 2516/4885FFAR1 149/4885FNTA 117/4885 |
| US-12551490-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, FADS2 | L3MBTL1 2521/4885FFAR1 25/4885FNTA 446/4885 |
| US-11622968-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, SCD | L3MBTL1 2485/4885FFAR1 133/4885FNTA 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.